Roivant Sciences Ltd (ROIV) concluded trading on Wednesday at a closing price of $11.69, with 5.81 million shares of worth about $67.87 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 8.24% during that period and on December 18, 2024 the price saw a loss of about -3.79%. Currently the company’s common shares owned by public are about 733.33M shares, out of which, 375.36M shares are available for trading.
Stock saw a price change of -3.47% in past 5 days and over the past one month there was a price change of 4.75%. Year-to-date (YTD), ROIV shares are showing a performance of 4.10% which increased to 7.15% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $9.69 but also hit the highest price of $13.06 during that period. The average intraday trading volume for Roivant Sciences Ltd shares is 5.88 million. The stock is currently trading -4.03% below its 20-day simple moving average (SMA20), while that difference is down -1.74% for SMA50 and it goes to 3.53% higher than SMA200.
Roivant Sciences Ltd (NASDAQ: ROIV) currently have 733.33M outstanding shares and institutions hold larger chunk of about 67.66% of that.
The stock has a current market capitalization of $8.51B and its 3Y-monthly beta is at 1.26. PE ratio of stock for trailing 12 months is 2.07, while it has posted earnings per share of $5.66 in the same period. It has Quick Ratio of 10.43 while making debt-to-equity ratio of 0.01. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ROIV, volatility over the week remained 2.81% while standing at 2.78% over the month.
Stock’s fiscal year EPS is expected to drop by -114.65% while it is estimated to decrease by -42.61% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Wolfe Research on February 15, 2024 offering an Outperform rating for the stock and assigned a target price of $17 to it. Coverage by Piper Sandler stated Roivant Sciences Ltd (ROIV) stock as an Overweight in their note to investors on January 05, 2024, suggesting a price target of $20 for the stock. On December 12, 2023, Deutsche Bank Initiated their recommendations, while on October 17, 2023, Guggenheim Initiated their ratings for the stock with a price target of $17. Stock get a Neutral rating from BofA Securities on June 08, 2023.